The world's scientific and social network for malaria professionals
Subscribe to free Newsletter | 10651 malaria professionals are enjoying the free benefits of MalariaWorld today

drug resistance

Assessing the in vitro sensitivity with associated drug resistance polymorphisms in Plasmodium vivax clinical isolates from Delhi, India

November 25, 2020 - 12:42 -- Open Access
Author(s): 
Matlani M, Kumar A, Singh V
Reference: 
Exp Parasitol. 2020 Nov 19:108047

The drug resistance of Plasmodium vivax in clinical cases remains largely unknown till date because of the difficulty in diagnosing the resistant P. vivax strains. The present study was undertaken to determine the prevalence of mutant alleles in drug resistance genes viz P. vivax multi-drug resistance (pvmdr-1), chloroquine resistance transporter (pvcrt-o), dihydrofolate reductase (pvdhfr) and dihydropteroate synthase (pvdhps) along with in vitro chloroquine (CQ) sensitivity in P. vivax clinical isolates.

Molecular surveillance of antimalarial partner drug resistance in sub-Saharan Africa: a spatial-temporal evidence mapping study

November 18, 2020 - 12:27 -- Open Access
Author(s): 
Hanna Y Ehrlich, Justin Jones, Sunil Parikh
Reference: 
Lancet Microbe. 2020 Sep;1(5):e209-e217.

Molecular markers for antimalarial drug resistance can be used to rapidly monitor the emergence and spatial distribution of resistance to artemisinin-based combination therapies (ACTs). Little has been done to analyse molecular surveillance efforts or to assess surveillance coverage. This study aimed to develop an evidence map to characterise the spatial-temporal distribution and sampling methodologies of drug resistance surveillance in sub-Saharan Africa, specifically focusing on markers associated with ACT partner drugs.

Identification of tyrosine kinase inhibitors that halt Plasmodium falciparum parasitemia

November 17, 2020 - 13:05 -- Open Access
Author(s): 
Kesely K, Noomuna P, Vieth M, Hipskind P, Haldar K, Pantaleo A, Turrini F, Low PS
Reference: 
PLoS One. 2020 Nov 12;15(11):e0242372

Although current malaria therapies inhibit pathways encoded in the parasite's genome, we have looked for anti-malaria drugs that can target an erythrocyte component because development of drug resistance might be suppressed if the parasite cannot mutate the drug's target. In search for such erythrocyte targets, we noted that human erythrocytes express tyrosine kinases, whereas the Plasmodium falciparum genome encodes no obvious tyrosine kinases.

A snapshot of Plasmodium falciparum malaria drug resistance markers in Sudan: a pilot study

November 10, 2020 - 14:22 -- Open Access
Author(s): 
Mohamed NS, Abdelbagi H, Sibley CH, et al.
Reference: 
BMC Res Notes. 2020 Nov 7;13(1):512

Malaria infection is still known to be a worldwide public health problem, especially in tropical and sub-tropical African countries like Sudan. A pilot study conducted to describe the trend of P. falciparum drug resistance markers in 2017–2018 in comparison to CQ and AS/SP eras in Sudan. The Pfcrt, Pfmdr-1, Pfdhfr, and Pfdhps genes were investigated. Data deposited by the worldwide antimalarial resistance network was consulted, and the molecular markers previously reported from Sudan were analyzed.

NOT Open Access | In silico assessment of natural products and approved drugs as potential inhibitory scaffolds targeting aminoacyl-tRNA synthetases from Plasmodium

November 3, 2020 - 14:45 -- NOT Open Access
Author(s): 
Doshi K, Pandya N, Datt M
Reference: 
3 Biotech. 2020 Nov;10(11):470

Malaria remains the leading cause of deaths globally, despite significant advancement towards understanding its epidemiology and availability of multiple therapeutic interventions. Poor efficacy of the approved vaccine, and the rapid emergence of antimalarial drug resistance, warrants an urgent need to expedite the process of development of new lead molecules targeting malaria.

Synthesis and Antiplasmodial Activity of Novel Fosmidomycin Derivatives and Conjugates with Artemisinin and Aminochloroquinoline

October 31, 2020 - 10:00 -- Open Access
Author(s): 
Palla D, Antoniou AI, Baltas M, Menendez C, Grellier P, Mouray E, Athanassopoulos CM.
Reference: 
Molecules. 2020 Oct 21;25(20):E4858

Malaria, despite many efforts, remains among the most problematic infectious diseases worldwide, mainly due to the development of drug resistance by Plasmodium falciparum. The antibiotic fosmidomycin (FSM) is also known for its antimalarial activity by targeting the non-mevalonate isoprenoid synthesis pathway, which is essential for the malaria parasites but is absent in mammalians.

Not Open Access | Describing the current status of Plasmodium falciparum population structure and drug resistance within mainland Tanzania using molecular inversion probes

October 28, 2020 - 10:19 -- NOT Open Access
Author(s): 
Moser KA, Madebe RA, Bailey JA, et al.
Reference: 
Mol Ecol. 2020 Oct 26

High-throughput Plasmodium genomic data is increasingly useful in assessing prevalence of clinically important mutations and malaria transmission patterns. Understanding parasite diversity is important for identification of specific human or parasite populations that can be targeted by control programs, and to monitor the spread of mutations associated with drug resistance. An up-to-date understanding of regional parasite population dynamics is also critical to monitor the impact of control efforts.

Not Open Access | Nanotized curcumin-benzothiophene conjugate: A potential combination for treatment of cerebral malaria

October 13, 2020 - 12:50 -- NOT Open Access
Author(s): 
Ghosh A, Banerjee T
Reference: 
IUBMB Life. 2020 Oct 9.

The declining effectiveness of the available antimalarial drugs due to drug resistance requires a continued effort to develop new therapeutic approaches. In this context, combination therapies hold a great promise for developing effective first-line antimalarial treatments for reducing malaria mortality. The present study explores the antimalarial efficacy of nanotized formulation of curcumin in combination with benzothiophene compound 6 (3-bromo-N-(4-fluorobenzyl)-benzo[b]thiophene-2-carboxamide) with a view to achieve better efficacy at a very low dose in comparison to that accomplished with monotherapy alone.

NOT Open Access | Associations between malaria preventive regimens and Plasmodium falciparum drug resistance mediating polymorphisms in Ugandan pregnant women

October 7, 2020 - 15:35 -- NOT Open Access
Author(s): 
Nayebare P, Asua V, Conrad MD, Kajubi R, Kakuru A, Nankabirwa JI, Muhanguzi D, Dorsey G, Kamya MR, Nsobya S, Rosenthal PJ
Reference: 
Antimicrob Agents Chemother. 2020 Oct 5:AAC.01047-20

Intermittent preventive treatment in pregnancy (IPTp) with monthly sulfadoxine-pyrimethamine (SP) is recommended for malaria-endemic parts of Africa, but efficacy is compromised by resistance and, in recent trials, dihydroartemisinin-piperaquine (DP) has shown better antimalarial protective efficacy. We utilized blood samples from a recent trial to evaluate selection by IPTp with DP or SP of Plasmodium falciparum genetic polymorphisms that alter susceptibility to these drugs.

NOT Open Access | Combination between antibacterial and antifungal antibiotics with phytocompounds of Artemisia annua L: A strategy to control drug resistance pathogens

October 1, 2020 - 15:50 -- NOT Open Access
Author(s): 
Rolta R, Sharma A, Sourirajan A, Mallikarjunan PK, Dev K
Reference: 
J Ethnopharmacol. 2020 Sep 27:113420

Artemisia annua L. is a traditional Chinese medicine used for the treatment of malaria, jaundice and intense fever.

Pages

Subscribe to RSS - drug resistance